Bionano Genomics, Inc.

https://www.bionano.com

Bionano Genomics, Inc. is a genome analysis company headquartered in San Diego, California. Its mission is to empower researchers and clinicians with advanced genomic analysis tools to unlock new discoveries and improve patient care, striving to elevate health and wellness for all through its optical genome mapping (OGM) solutions.

The company's core offerings include the Saphyr and Stratys™ optical genome mapping systems, DLS™ reagents, and the Bionano Access™, Bionano Solve™, and VIA™ software suites for data analysis and interpretation. Bionano also provides contract genome mapping services and offers diagnostic testing through its Lineagen business, focusing on conditions like autism spectrum disorder and other neurodevelopmental disabilities. Additionally, its CLIA-certified Bionano Laboratories provides OGM-based laboratory developed tests. These solutions are utilized by academic research institutions, biotechnology and pharmaceutical companies, clinical laboratories, and government agencies for applications in cancer genomics, rare disease diagnostics, and translational research.

Led by CEO Erik Holmlin, Bionano Genomics is positioned as a leader in OGM technology, providing critical tools for detecting structural variants often missed by other genomic methods. The company reported Q4 2025 revenue of $8.0 million and full-year 2025 revenue of $28.5 million, with a gross margin of 46%. Recent studies have demonstrated OGM's superior performance over traditional methods in analyzing conditions like multiple myeloma, and the company continues to see an increase in OGM studies presented at major scientific meetings. Bionano is currently undergoing a strategic transformation to enhance cash efficiency and concentrate on its core OGM business.

Latest updates

Bionano Study Validates OGM’s Potential in Multiple Myeloma Analysis

Event summary

  • A study published in the American Journal of Hematology demonstrates Bionano Genomics’ optical genome mapping (OGM) outperforms traditional methods in multiple myeloma (MM) analysis.
  • The study, involving 211 MM samples—the largest cohort to date—compared OGM (n=100) with karyotyping (n=155), FISH (n=209), and next-generation sequencing (NGS).
  • OGM identified relevant abnormalities in 92% of cases previously deemed normal by karyotyping and resolved 82% of samples that previously failed karyotype.
  • The study found OGM detected additional pathogenic structural abnormalities in approximately 30% of subjects and uncovered complex genomic events in 29%.

The big picture

Multiple myeloma diagnostics have historically relied on techniques with limited sensitivity, contributing to treatment challenges. This study validates OGM’s potential to improve diagnostic accuracy and potentially impact treatment outcomes, positioning Bionano to capture a share of a market increasingly focused on precision oncology. The validation by Johns Hopkins and MD Anderson lends significant credibility to OGM’s utility in a complex and challenging area of hematological malignancy.

What we're watching

Adoption Rate
The pace at which clinical labs integrate OGM into their MM workflows will determine the near-term revenue impact for Bionano, given the study’s recommendation for workflow revision.
Regulatory Approval
Whether Bionano can secure regulatory clearances or guidance related to OGM’s use in MM diagnostics will be critical for broader clinical adoption and reimbursement.
Competitive Landscape
The extent to which NGS and other cytogenetic techniques adapt to address OGM’s advantages will shape Bionano’s long-term market share in MM analysis.

Bionano Genomics Revenue Declines as Flowcell Sales Fall

Event summary

  • Bionano Genomics reported Q4 2025 revenue of $8.0 million, a 3% decrease year-over-year.
  • Full-year 2025 revenue totaled $28.5 million, down 7% from 2024.
  • Flowcell sales decreased by 6% in Q4 2025 to 7,554 units, and by 0.2% for the full year to 30,171.
  • The company installed 9 new OGM systems in Q4 2025, bringing the total installed base to 387 systems.

The big picture

Bionano's revenue decline, coupled with decreasing flowcell sales, suggests challenges in market adoption despite positive developments like the CLFS increase and growing scientific validation. The company's ability to reverse this trend hinges on demonstrating the clinical utility of OGM and expanding its application beyond hematologic malignancies, while managing costs effectively. The installed base growth, while positive, needs to translate into increased utilization to drive revenue growth.

What we're watching

Revenue Trajectory
Whether the anticipated revenue growth in 2026, guided between $30 and $33 million, can be achieved given the current downward trend and the impact of discontinued clinical services in the prior year.
Flowcell Demand
How the company will address the continued decline in flowcell sales, which is a key driver of consumables revenue and overall profitability.
Regulatory Impact
The extent to which the 47% increase in the Clinical Lab Fee Schedule payment determination will translate into increased adoption and revenue for OGM services in hematologic malignancies.

Bionano Genomics Sees OGM Adoption Accelerate Amid Genomics Data Sharing

Event summary

  • Bionano Genomics reported a two-fold increase in Optical Genome Mapping (OGM) studies presented at the 2026 ACMG Annual Meeting, totaling twelve presentations.
  • Four presentations were oral, and eight were poster presentations, covering applications in cancer genomics, rare diseases, and reproductive disorders.
  • Greenwood Genetic Center hosted an 'Ask the OGM Expert' workshop, and Baylor Genetics launched a commercial service providing OGM data to the research community.
  • The presentations highlighted OGM's ability to detect structural variants often missed by other genomic analysis techniques.

The big picture

Bionano's announcement signals a potential shift towards more comprehensive genomic analysis, particularly in areas like rare disease diagnosis and cancer research where structural variant detection is crucial. The increased adoption of OGM, coupled with the data sharing initiative from Baylor Genetics, suggests a move towards greater collaboration and data accessibility within the genomics research community. However, the company's success hinges on demonstrating consistent clinical utility and securing reimbursement for its OGM services, a challenge given the competitive landscape of genomic sequencing.

What we're watching

Adoption Rate
The pace at which broader adoption of OGM services by clinical labs and research institutions will validate the commercial viability of Baylor Genetics’ new data sharing service.
Competitive Landscape
How the increased visibility of OGM’s capabilities will affect the competitive dynamics with existing short-read and long-read sequencing technologies.
Clinical Validation
Whether the real-world evidence presented at ACMG will translate into increased clinical utility and reimbursement for OGM-based diagnostic testing.

Bionano Symposium Highlights Scaling Path for Optical Genome Mapping

Event summary

  • Bionano Genomics hosted Symposium 2026, concluding February 27, 2026, with over 1,250 registrants and 35 speakers.
  • Laboratories in the US, Canada, and Europe described scaling optical genome mapping (OGM) to process up to 3,000 samples per year with automation.
  • Radboud University Medical Center has automated UHMW DNA isolation and labeling, currently processing 500 samples and targeting 3,000 annually.
  • Bionano’s Ionic system enables purification of DNA and RNA from FFPE samples, potentially improving NGS assay performance.
  • Dr. Adam Smith (Labcorp) indicated OGM adoption requires less than 1/8 of the initial investment compared to long-read sequencing for 1,000 samples.

The big picture

Bionano's Symposium highlights a shift towards scalable genomic analysis, particularly in hematologic malignancies and constitutional disorders. The emphasis on automation and integration with existing workflows suggests a move away from purely research applications towards clinical diagnostics. While OGM offers a compelling alternative to long-read sequencing in terms of cost and throughput, Bionano must demonstrate consistent performance and ease of use to achieve widespread adoption and capture a meaningful share of the rapidly evolving cytogenomics market.

What we're watching

Adoption Rate
The pace at which Bionano can convert pilot programs and research use into commercially viable, high-volume diagnostic workflows will determine its long-term revenue potential.
Competitive Landscape
How Bionano’s cost and scalability advantages against long-read sequencing will hold up as competitors innovate and potentially lower their own costs.
Software Integration
The success of OMKar and VIA’s integration with existing laboratory information management systems (LIMS) will be critical for streamlining workflows and driving broader adoption.

Bionano Symposium Highlights OGM's Growing Role in Rare Disease Diagnostics

Event summary

  • Bionano Symposium 2026 Day 3 focused on Optical Genome Mapping (OGM) applications in constitutional genetic disorders.
  • Presentations included findings from Japan, India, Brazil, the Netherlands, Turkey, and the United States, with over 1,200 attendees from 73 countries.
  • OGM identified pathogenic variants in 20% of rare disease cases and 12% of previously negative microarray/exome sequencing cases.
  • Bionano’s VIA software is being highlighted as a tool to facilitate OGM data interpretation and standardize workflows.

The big picture

Bionano’s OGM technology addresses a critical need in constitutional genetic disorder diagnostics, where traditional methods often fail to identify the underlying causes. The company's focus on rare diseases, collectively affecting millions, represents a significant market opportunity, but success hinges on demonstrating clinical utility and securing reimbursement. The symposium highlights the growing recognition of OGM's potential, but also underscores the challenges of integrating a novel technology into established clinical workflows.

What we're watching

Adoption Rate
The pace of adoption of OGM in clinical diagnostics will depend on reimbursement models and integration into existing lab workflows, which remains a significant hurdle.
Data Validation
The statistical significance of OGM’s findings in previously negative cases (12%) requires further validation across larger, more diverse cohorts to avoid false positives.
Competitive Landscape
The emergence of alternative structural variant detection technologies could challenge Bionano’s market position, particularly if they offer comparable results at a lower cost.

Bionano Symposium Highlights Growing Adoption of Optical Genome Mapping in Oncology and Cell Therapy

Event summary

  • Bionano Symposium 2026, held February 25, 2026, featured 11 presentations focused on oncology and bioprocessing applications of Optical Genome Mapping (OGM).
  • The symposium drew over 1,150 registered participants from 73 countries, marking it as the largest global event dedicated to Bionano solutions this year.
  • Dr. Hippolyte Guerineau’s study of 214 multiple myeloma samples demonstrated OGM’s ability to reveal additional structural complexity compared to FISH.
  • Dr. Ying Zou and Dr. Alejandro Berenguer Rubio’s research on rare sarcomas detected structural variants in over 70% of cases with normal karyotypes, revealing previously missed genomic rearrangements.

The big picture

Bionano’s OGM technology is positioned to capitalize on the growing demand for high-resolution genomic analysis in both oncology and cell/gene therapy. The presentations at Symposium 2026 underscore a shift towards more complex genomic profiling, moving beyond traditional methods like FISH and sequencing. However, widespread adoption hinges on demonstrating consistent clinical utility and navigating regulatory hurdles, particularly as applications expand into solid tumors.

What we're watching

Adoption Rate
The pace at which the FrOGG consortium’s standardization efforts and centralized data hub drive broader adoption of OGM across Europe and beyond will be a key indicator of Bionano’s long-term success.
Regulatory Scrutiny
How the FDA’s continued recognition of OGM’s utility in cell and gene therapy development impacts Bionano’s regulatory pathway and commercialization timelines warrants close monitoring.
Solid Tumor Expansion
Whether the momentum from the sarcoma studies can translate into broader adoption of OGM in other solid tumor types, expanding Bionano’s addressable market beyond hematological malignancies, remains to be seen.

Bionano Symposium Highlights Optical Genome Mapping's Growing Role in Hematologic Malignancy Research

Event summary

  • The Bionano Symposium 2026, focused on Optical Genome Mapping (OGM) for hematologic malignancies, drew over 1000 registered attendees from 70 countries.
  • Presentations showcased OGM's ability to detect structural variants and accelerate genomic analysis of leukemias, lymphomas, and multiple myeloma, often in conjunction with next-generation sequencing (NGS).
  • Dr. Alka Chaubey, Bionano’s chief medical officer, presented advancements in the OGM workflow and highlighted its expanding role in cytogenomics.
  • Researchers reported high concordance between OGM and traditional cytogenetic methods while emphasizing OGM’s ability to resolve complex rearrangements and identify novel driver events.

The big picture

Bionano’s OGM technology represents a shift towards more comprehensive genomic analysis in hematologic malignancies, moving beyond traditional methods like karyotyping and FISH. The symposium underscores the growing recognition of structural variants’ role in cancer development and the potential for OGM to improve diagnostic accuracy and treatment selection. While the technology shows promise, its success hinges on widespread adoption within clinical and research settings, which requires demonstrating clear clinical utility and cost-effectiveness.

What we're watching

Adoption Rate
The pace at which hematology labs integrate OGM into routine workflows will determine Bionano’s revenue growth, particularly given the need for specialized training and equipment.
Competitive Landscape
How NGS providers and other cytogenetic assay developers respond to OGM’s capabilities will shape Bionano’s market share and pricing power.
Clinical Validation
The extent to which OGM’s clinical utility is validated through larger, prospective studies will influence its adoption by clinicians and reimbursement coverage.

Bionano Symposium Highlights Optical Genome Mapping's Expanding Role in Oncology and Diagnostics

Event summary

  • Bionano Genomics is hosting its annual virtual symposium, Bionano Symposium 2026, from February 23-26, 2026.
  • The symposium will feature over 30 researchers from North America, Europe, and Asia presenting on optical genome mapping (OGM) applications.
  • Key research areas covered include hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene/cell therapy.
  • The event includes scientific presentations, panel discussions, and a virtual poster hall, with sessions beginning at 7:00 AM PST.

The big picture

Bionano's symposium underscores the growing recognition of optical genome mapping as a valuable tool in genomic analysis, particularly for complex disease diagnostics and therapeutic development. While OGM offers advantages in detecting structural variants, its adoption hinges on demonstrating clear clinical utility and cost-effectiveness compared to existing technologies. The event signals Bionano’s continued effort to expand the applications and market reach of its platform within a competitive and evolving genomics landscape.

What we're watching

Adoption Rate
The pace at which the showcased applications of OGM translate into broader clinical adoption will be a key indicator of Bionano's long-term success, particularly given the relatively nascent stage of the technology.
Competitive Landscape
Whether Bionano can maintain its technological lead and fend off competition from established genomics players offering alternative sequencing methods remains a critical risk factor.
Workflow Integration
How effectively Bionano’s tools and software integrate into existing laboratory workflows will determine the ease of adoption and ultimately impact the scalability of OGM implementation.

Bionano Study Validates OGM for Gene Editing QC, Bolsters Market Position

Event summary

  • A peer-reviewed study published in *Molecular Therapy - Methods & Clinical Development* details the use of Bionano’s optical genome mapping (OGM) to detect genomic alterations introduced by gene editing technologies.
  • The study found OGM detected structural variants and copy number changes that traditional methods missed, particularly with transposon and lentiviral transduction.
  • OGM demonstrated sensitivity to variant allele fractions as low as 5%, enabling detection of subtle genomic changes.
  • The research highlights OGM’s potential as a quality control (QC) tool for cell-line genome integrity in gene editing therapy development.

The big picture

The gene editing therapy market is rapidly expanding, creating a critical need for robust quality control measures to ensure patient safety and therapeutic efficacy. This study validates Bionano’s OGM technology as a potentially superior QC tool compared to existing methods, positioning the company to capitalize on this growing demand. The ability to detect subtle genomic alterations is increasingly important as gene editing techniques become more precise and complex, and regulators demand higher levels of fidelity.

What we're watching

Adoption Rate
The pace at which gene editing therapy developers integrate OGM into their QC workflows will determine Bionano’s near-term revenue growth and market penetration.
Competitive Landscape
How competing genomic analysis technologies respond to OGM’s demonstrated advantages in detecting complex structural variants will shape Bionano’s long-term market share.
Regulatory Impact
Whether regulatory bodies increasingly mandate or recommend OGM-based QC for gene editing therapies will significantly expand Bionano’s addressable market.

Bionano Revenue Declines as OGM Adoption Progresses

Event summary

  • Bionano Genomics reported preliminary Q4 2025 revenue between $7.8M and $8.0M, a 2-4% year-over-year decrease.
  • Full-year 2025 revenue is projected at $28.4M to $28.6M, down 7-8% year-over-year.
  • The company installed 9 new OGM systems in Q4 and 32 for the full year, bringing the total installed base to 387.
  • Bionano secured a second Category I CPT code for OGM use in constitutional genetic disorders, with a 47% increase in payment determination for hematologic malignancies.

The big picture

While Bionano highlights progress in reimbursement and software upgrades, the revenue decline signals challenges in driving widespread OGM adoption. The company’s strategic shift towards routine users appears to be underway, but the financial results suggest this transition is not yet translating into significant growth. The long-term viability of Bionano hinges on demonstrating the clinical and economic value of OGM to a broader customer base.

What we're watching

Financial Trajectory
Whether Bionano can reverse the year-over-year revenue decline and achieve sustained growth will depend on accelerating OGM adoption and expanding reimbursement coverage.
CPT Code Impact
The full impact of the second Category I CPT code on revenue generation and adoption rates remains to be seen and will be a key indicator of future success.
Competitive Landscape
The pace at which competitors develop and deploy alternative genomic analysis solutions will influence Bionano’s ability to maintain its market position and pricing power.
CID: 241